Since April, MAKO Medical, a College of American Pathologists (CAP) accredited laboratory, has processed almost 4 million COVID-19 tests from more than 20 states in the U.S. MAKO partners with medical providers, employers and governments – turning around COVID-19 test results in what one state leader called an “ultra-fast” way.
MAKO just released a targeted next generation sequencing research panel that covers more than 99% of the SARS-Cov-2 genome. With this new panel, MAKO is able to detect the new B117 variant of COVID-19 that was first reported in the United Kingdom. Additionally, this new NGS research panel gives MAKO the capabilities to detect new variants caused by COVID-19 mutations that may arise giving public health leaders access to the most recent data.
MAKO now offers clients and partners the entire end-to-end solution for COVID-19 response from antigen to antibody to PCR to sequencing. MAKO is the one-stop-shop for laboratory services.
COVflu-19™ is MAKO Medical’s SARS-CoV-2 + Influenza A + Influenza B diagnostics test. COVflu-19 detects and differentiates RNA from multiple respiratory viruses simultaneously. Collected via nasopharyngeal and nasal swabs, COVflu-19 is run on the highly accurate, real time PCR instruments, specifically Life Technologies QuantStudio 12k Flex Systems and uses the Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit assay.
COVflu-19 gets a targeted specificity to 100% of currently available complete genomes for SARS-CoV-2 and robust performance for detecting Flu A and B strains, providing increased confidence in results.
Offering expanded capacity and increased diagnostic capabilities during this time of crisis.
In response to the novel coronavirus (SARS-CoV-2), MAKO Medical Laboratories has worked rapidly to develop a new multiplex real-time RT-PCR diagnostic test to enable clinical and government providers to quickly diagnose COVID-19 caused by SARS-CoV-2 infection.
Watch how MAKO is working around the clock in the battle against coronavirus:
We are honored to serve our country and citizens through this pandemic and will continue to actively invest in infrastructure and expanded capacity to meet the local, state, and federal needs.
What NC Providers are saying:
“MAKO’s partnership during this pandemic and commitment to accurate resulting and efficient turn times has had a tremendously positive impact on our response and allocation of resources. As important, it’s relieved staff and patient anxieties – a critical factor to manage in any health crisis.”
Bert Beard, CEO of Maria Parham, a Duke Life Point Hospital
“MAKO Medical has proven to be a true laboratory partner for FirstHealth of the Carolinas. During this COVID-19 crisis, when every hospital bed is needed and every illness could be an emergency, MAKO has not only met our needs, but has gone above and beyond to exceed our expectations.
Their willingness to pick up and transport potential COVID-19 test samples has allowed for the rapid turnaround of test results – many in the same day. This testing capability ensures we have the capacity to care for our patients and helps us preserve valuable hospital resources.”
Brian Canfield, Chief Operating Officer at FirstHealth Moore Regional Hospital
The COVID-19 pandemic brought many businesses to a standstill. Now it’s time to get our country moving again.
MAKO Medical is currently offering businesses across the country a major competitive advantage coming out of the COVID-19 crisis: SARS-CoV-2 IgG testing, the complete back-to-work solution. As a full service CAP-accredited lab, we do the screenings, we run the tests, we provide the results. And most importantly, we can get your business moving again – quickly.
MAKO Medical Laboratories is a CLIA and CAP accredited laboratory. MAKO Medical Laboratories deploys the Applied Biosystems TaqPath COVID-19 Combo Assay. This is a fast, highly sensitive multiplex diagnostic solution that is needed for the real-time PCR detection of RNA from the SARS-CoV-2 virus.
MAKO Medical Laboratories’ COVID-19 test was validated and independently tested in two separate laboratories. Our team performed two bridging studies with 70 samples, 35 positive and 35 negative. There was 100% reconfirmation and no discordance with both studies.
Additionally, MAKO Medical Laboratories performed a Limit of Detection study according to FDA guidelines. MAKO Medical Laboratories demonstrated comparable Limits of Detection to the Applied Biosystems TaqPath COVID-19 Combo Assay emergency use authorization.
MAKO Medical Laboratories’ validation and verification has been signed off by our Laboratory Director, Dr. Chad Rund.
North Carolina Health Secretary Dr. Mandy Cohen warned on Friday that the COVID-19 variant, first detected in the United Kingdom, is likely here in the state now. This comes as the FDA is looking at the potential impact mutations can have on COVID-19 testing and the potential for a false negative.Read More
MAKO Medical Laboratories surpassed another significant milestone by processing the 4 millionth COVID-19 test at its Vance County facility. Since April, the College of American Pathologists (CAP) accredited laboratory has delivered on its commitment to provide rapid, reliable COVID-19 test results to communities across the United States.Read More
MAKO Medical Laboratories, a leader in full service laboratory and COVID-19 testing across the United States, celebrated Veterans Day with the American Legion Post 60 in Henderson by providing a free meal to all Vance County Veterans and their family members.Read More
A nation’s leader in testing during the COVID-19 pandemic, MAKO Medical Laboratories was named a North Carolina recipient of the Pro Patria Award from the U.S. Department of Defense’s Employer Support of the Guard and Reserve (ESGR).Read More